

# AIDS Research Advisory Committee Director's Report

January 26, 2004









#### NEW ARAC MEMBERS

- Ruth Ruprecht, M.D., Ph.D.; Chief, Laboratory of Viral Pathogenesis, Dana-Farber Cancer Institute
- Nathan Theilman, M.D.,M.P.H.;
   Assistant Professor of Medicine, Duke University Medical Center
- Debra Birx, M.D. Col. M.C. Director USMHRP, USAMRMC, DOD



NCI

**NIAID** 

### **NIH Budget**

**2003 2004** (pending)

\$4.6B \$4.7B

\$3.7B \$4.3B

(15.4%)
Others \$18.9B \$19.0B


Total \$27.2B \$28.0B




### NIAID Budget Comparison

**Including Global Fund** 

### FY 2003 Comparable



### FY 2004 Revised Conference



\$3.704B

\$4.305B



### AIDS Spending by Institute and Center (Dollars in thousands)

	FY 2002	FY 2003	FY 2004
Institute/Center	Actual	Estimate	Estimate
NIAID	\$1,185,660	\$1,345,004	\$1,407,356
NIDA	278,372	303,487	315,011
NCI	254,252	265,009	269,615
NIMH	163,007	175,996	182,390
NCRR	134,791	146,920	153,464
NICHD	115,647	125,985	131,133
NHLBI	70,906	75,380	75,524
NIGMS	48,391	52,385	54,894
NINDS	42,166	45,562	47,456
NIDDK	25,925	29,708	31,024
NIAAA	23,950	25,886	26,944
NIDCR	23,267	24,737	25,357
FIC	18,317	21,411	22,740
NEI	12,730	12,777	12,746
NINR	10,978	11,877	12,155
NIEHS	8,248	8,589	8,789
NLM	6,677	7,177	7,477
NIAMS	6,302	6,621	6,759
NHGRI	6,247	6,641	6,925
NIA	4,985	5,320	5,519
NCCAM	2,552	2,718	2,818
NIDCD	1,737	1,738	1,758
NIBIB	972	972	1,062
SUBTOTAL	2,446,079	2,701,900	2,808,916
OD	53,379	58,040	60,942
TOTAL	\$2,499,458	\$2,759,940	\$2,869,858



### AIDS Spending by Institute and Center (Dollars in thousands)

FY2002 FY2003 FY2004

NIAID 1,185,660 1,345,004 1,407,356

Others 1,313,798 1,414,936 1,462,502



### VaxGen -- Update

- NIAID Consultation Group formed to re-analyze data
- Re-analysis results to be presented at Conference of Retroviruses and Opportunistic Infections (February 2004) by D. Follman, Director, Center for Biostatistics, NIAID
- Plenary presentation of re-analysis by D. Follman and G. Counts (HVTN) at National African American AIDS Conference, March 2004
- Follow-up workshop for community input/discussion



### VaxGen – Lessons Learned

 Future HIV vaccine trials will include appropriate enrollment of African Americans, Latinos, and women (if possible)



#### Thai Trial

- DoD/NIAID Phase III trial underway
- Science Policy Forum article 16 January, 2004
- Trial discussed at AVRWG 14 Jan.
- NIAID statement issued in response to questions
- NIAID formal response being submitted to Science as "policy piece"



## AIDS Vaccine Research Working Group – Update

 Highlights of most recent meeting (January 2004) provided in your packets



### **Networks**



### Mission Statement

The mission of DAIDS is to help ensure an **end** to the HIV/AIDS epidemic by increasing basic knowledge of the pathogenesis and transmission of HIV, supporting the development of therapies for HIV infection and its complications, and supporting the development of vaccines and other prevention strategies.



**Facts** 

**Budget** 

unsolicited ~25%

solicited ~75%

basic (discovery) ~25%

clinical ~75% (\$400M)

Stable budget



**Facts** 

extension – all re-compete 06

10 Network bodies
AACTG, PACTG, CPCRA, HPTN,
HVTN, AIEDRP, ESPRIT

Phidisa, DOD, CDC



Review and Discussions Began in October 2001 Has involved network leaders, community, DAIDS All have agreed that present structure has been effective but not efficient and not well suited for international research